Neurocrine Biosciences, Inc.
NBIX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $794,900 | $687,500 | $572,600 | $627,700 |
| % Growth | 15.6% | 20.1% | -8.8% | – |
| Cost of Goods Sold | $14,000 | $11,300 | $9,200 | $9,300 |
| Gross Profit | $780,900 | $676,200 | $563,400 | $618,400 |
| % Margin | 98.2% | 98.4% | 98.4% | 98.5% |
| R&D Expenses | $250,000 | $244,300 | $263,200 | $185,600 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $291,600 | $286,300 | $276,500 | $287,800 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $300 | $0 | $100 | $3,000 |
| Operating Expenses | $541,900 | $530,600 | $539,800 | $476,400 |
| Operating Income | $239,000 | $145,600 | $23,600 | $142,000 |
| % Margin | 30.1% | 21.2% | 4.1% | 22.6% |
| Other Income/Exp. Net | $52,800 | $13,900 | -$8,900 | $20,600 |
| Pre-Tax Income | $291,800 | $159,500 | $14,700 | $162,600 |
| Tax Expense | $82,300 | $52,000 | $6,800 | $59,500 |
| Net Income | $209,500 | $107,500 | $7,900 | $103,100 |
| % Margin | 26.4% | 15.6% | 1.4% | 16.4% |
| EPS | 2.11 | 1.09 | 0.08 | 1.03 |
| % Growth | 93.6% | 1,262.5% | -92.2% | – |
| EPS Diluted | 2.04 | 1.06 | 0.08 | 1 |
| Weighted Avg Shares Out | 99,400 | 99,000 | 99,700 | 100,000 |
| Weighted Avg Shares Out Dil | 102,500 | 101,000 | 102,500 | 102,900 |
| Supplemental Information | – | – | – | – |
| Interest Income | $22,200 | $20,600 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $7,700 | $7,300 | $7,600 | $7,100 |
| EBITDA | $299,500 | $152,900 | $31,300 | $181,700 |
| % Margin | 37.7% | 22.2% | 5.5% | 28.9% |